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Background: Notwithstanding its beneficial immunoprophylactic outcomes regarding 
leprosy and childhood TB, BCG vaccination may cause adverse events, particularly 
of the skin. However, this local hyper-immune reactivity cannot be predicted before 
vaccination, nor is its association with protection against leprosy known. In this study 
we investigated the occurrence of adverse events after BCG (re)vaccination in contacts 
of leprosy patients and analyzed whether the concomitant systemic anti-mycobacterial 
immunity was associated with these skin manifestations.
Methods: Within a randomized controlled BCG vaccination trial in Bangladesh, 14,828 
contacts of newly diagnosed leprosy patients received BCG vaccination between 2012 
and 2017 and were examined for adverse events 8 to 12 weeks post-vaccination. From 
a selection of vaccinated contacts, venous blood was obtained at follow-up examination 
and stimulated with Mycobacterium leprae (M. leprae) antigens in overnight whole-blood 
assays (WBA). M. leprae phenolic glycolipid-I-specific antibodies and 32 cytokines were 
determined in WBAs of 13 individuals with and 13 individuals without adverse events 
after vaccination.
results: Out of the 14,828 contacts who received BCG vaccination, 50 (0.34%) 
presented with adverse events, mainly (80%) consisting of skin ulcers. Based on the 
presence of BCG scars, 30 of these contacts (60%) had received BCG in this study as a 
booster vaccination. Similar to the pathological T-cell immunity observed for tuberculoid 
leprosy patients, contacts with adverse events at the site of BCG vaccination showed 
elevated IFN-γ levels in response to M. leprae-specific proteins in WBA. However, 
decreased levels of sCD40L in serum and GRO (CXCL1) in response to M. leprae 
simultaneously indicated less T-cell regulation in these individuals, potentially causing 
uncontrolled T-cell immunity damaging the skin.
Conclusion: Skin complications after BCG vaccination present surrogate markers for 
protective immunity against leprosy, but also indicate a higher risk of developing tuber-
culoid leprosy.
Clinical Trial registration: Netherlands Trial Register: NTR3087.
Keywords: adverse events, BCG (re)vaccination, biomarker profiles, household contacts, protective immunity, 
leprosy, Mycobacterium leprae
TaBlE 1 | Characteristics of contacts with or without complication after BCG 
vaccination.
Contacts with 
complication 
after BCG
(% of total)
Contacts 
without 
complication 
after BCG
Total 
contacts who 
received BCG
p-value
Contacts 50 14,778 14,828 n.a.
Male 23 (0.34%) 6,677 6,700 0.91
Female 27 (0.33%) 8,101 8,128
Child (5–16 years) 21 (0.43%) 4,829 4,850 0.16
Adult 29 (0.29%) 9,949 9,978
No BCG scar 
visible
20 (0.32%) 6,336 6,356 0.68
BCG scar present 30 (0.35%) 8,430 8,460
Vaccination status 
unknown
0 12 12 n.a.
Index with MB 19a (4.08%) 447 466 0.08
Index with PB 26b (2.42%) 1,047 1,073
aOne household with a multibacillary (MB) index had two contacts with a BCG 
complication.
bOne household with a paucibacillary (PB) index case had two contacts with a BCG 
complication, another household even had four contacts with a BCG complication.
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inTrODUCTiOn
Despite effective treatment of leprosy patients with multidrug 
therapy (MDT), the global number of new cases has not declined 
during the past decennium (1). A plausible explanation for 
this status quo could be that contacts of leprosy patients are 
pro longed and repetitively exposed to Mycobacterium leprae  
(M. leprae) before treatment of index cases is initiated, leading to 
continued bacterial transmission. Therefore, new tools and meth-
odologies, such as immuno- and chemoprophylaxis regimens, are 
needed to interrupt transmission.
BCG vaccination offers variable protection against tubercu-
losis (2) and other mycobacterial diseases such as leprosy (3) 
and Buruli ulcer (4). Moreover, recently it has become clear that 
BCG can modulate the innate immune system also leading to 
protection through a mechanism referred to as trained immunity 
(5–7). The protective effect against TB thus induced in children 
by neonatal BCG vaccination influences cytokine responses to 
heterologous pathogens, an effect that is reported to be charac-
terized by decreased anti-inflammatory cytokine responses, but 
increased IL-6 (5, 8).
In a previous study, immunoprophylaxis by BCG vaccination 
of contacts of newly diagnosed leprosy patients in Bangladesh 
conferred 56% protection, but was not affected by previous child-
hood BCG vaccination (9).
Although chemoprophylaxis does not protect a given individ-
ual from subsequent exposure to bacilli, the use of a single-dose 
rifampicin (SDR) in contacts in that study showed prevention of 
56% in the first 2 years after chemoprophylaxis and treatment 
of the index case (10). Strikingly, if contacts had received BCG 
vaccination as part of a childhood vaccination program (as 
determined by the presence of a BCG-scar), the protective effect 
of SDR even reached 80%.
To investigate whether the effects of SDR and BCG can be 
complimentary, a cluster randomized controlled BCG vaccina-
tion trial is currently conducted in Bangladesh, analyzing the 
potential synergetic effect of these chemo- and immunoprophy-
lactics by comparing the effect of BCG vaccination alone versus 
BCG followed by SDR after 8 to 12  weeks to prevent leprosy 
in contacts of new leprosy cases (designated the MALTALEP 
trial) (11).
In Bangladesh, BCG is routinely given to infants as part of 
the neonatal vaccination scheme as a prophylactic vaccine against 
tuberculosis. The coverage of BCG vaccination is estimated to 
be 98%1. Based on the visibility of BCG vaccination scars, 8,430 
out of 14,779 contacts (57%) within this trial had received BCG 
vaccination at birth. However, since not all individuals receiving 
BCG develop a visible scar (12), this number is probably higher.
BCG vaccination has been reported to cause adverse effects 
within BCG childhood vaccination programs in endemic areas 
(13–16) as well as in BCG naïve individuals in leprosy and TB 
non-endemic areas (17–20). In the current study, we investigated 
the number and nature of adverse events occurring after BCG 
vaccination in the MALTALEP trial.
1 http://www.who.int/immunization/monitoring_surveillance/data/bgd.pdf 
(Accessed: March 19, 2018).
In addition, to investigate whether these adverse events can 
provide further insight into the protective effect of BCG, we 
analyzed cytokine production in M. leprae-antigen-stimulated 
whole-blood assays (WBA) of 13 contacts developing adverse 
events and 13 contacts matched for age and gender, lacking such 
complications.
MaTErialS anD METHODS
Study Population
Newly diagnosed leprosy patients and their household contacts 
(HCs) were recruited on a voluntary basis between 2012 and 2017 
(Table  1). Leprosy was diagnosed based on clinical and bacte-
riological analysis and classified according to Ridley and Jopling 
(21). Leprosy patients were treated according to WHO standards. 
Contacts of consecutively diagnosed new leprosy patients were 
included in the districts of Nilphamari, Rangpur, Thakurgaon, 
and Panchagarh, in the northwest of Bangladesh (11). Each con-
tact group consisted of around 15 contacts and were randomly 
assigned to receive BCG or BCG plus rifampicin. Immunization 
with BCG was given to all included contacts, when the index 
case received the second dose of MDT. At intake, before BCG 
vaccination, all contacts were examined for a BCG scar on the 
left upper arm. After 8 to 12  weeks, vaccinated contacts were 
reviewed for adverse events during follow-up examination. 
Contacts were categorized as household members (sharing either 
roof, kitchen or both) or direct neighbors. Contacts were excluded 
from the study according to criteria described previously.
leprosy Prevalence
During this study, the prevalence in the four districts (Nilphamari, 
Rangpur, Panchagarh and Thakurgaon) in the northwest of 
Bangladesh was 0.82 per 10,000 with a new case detection rate 
of 0.98 per 10,000 (monthly report of the Rural Health Program 
of these four districts).
TaBlE 2 | Characteristics of contacts with BCG-related complications and 
matched controls.
Complications no complications
Number of contacts 13 13
Average age (years) 33.8 36.2
Number of females 8 8
Number of males 5 5
Average no. of weeks between BCG 
and WBA
7.9 (1.0–13.5) 7.7 (4.0–10.0)
Presence of BCG scar before study 8 6
Average size of BCG scar/ulcer (in mm) 14.8 (4.5–27) 3.4 (2.5–4.5)
Received SDR before blood drawing 1b 3a
Received no SDR 12 10
aAll controls received SDR 2 weeks before blood was drawn.
bThe contacts with a complication after BCG vaccination received SDR 4 weeks before 
experiencing the adverse event at 13 weeks post vaccination.
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Ethics
The MALTALEP trial is performed according to standard Good 
Clinical Practice (GCP) guidelines.2 Participants were informed 
about the study objectives, the samples, and their right to refuse 
to take part in or withdraw from the study without consequences 
for their treatment. Written informed consent was obtained 
before enrollment from all participants. For illiterate people a 
thumb print was taken, and for minors under 16 years of age, the 
guardian’s additional consent was obtained. All patients received 
treatment according to national guidelines. Participants were 
informed about the potential adverse events of the trial, that free 
consultation and treatment would be offered in case of adverse 
events and requested to report any suspected adverse events to 
the responsible field worker. Ethical approval of the study-
protocol was obtained through the National Research Ethics 
Committee (Bangladesh Medical Research Council; Protocol no. 
BMRC/NREC/2010-2013/1534).
BCG Vaccination
Vaccination was performed between September 2012 and February 
2017. BCG was administered intradermally. The BCG vaccine 
used in this trial (Japan BCG Laboratory, Tokyo, Japan) is also 
used in the routine neonatal vaccination program of Bangladesh. 
Vaccines were stored at the State Immunization Program facilities 
in the four different districts of the study area and kept at 0–4°C 
throughout the fieldwork.
adverse Events
All contacts receiving vaccination were provided with a vaccina-
tion card with details on how to reach the researcher in case of 
questions or adverse events. Contacts with self-reported adverse 
events were examined by field staff. Additionally, all contacts 
were examined 8 to 12 weeks after administration of the BCG. 
Data on adverse events were collected on the MALTALEP 
Contact Registration forms and on a separate BCG complication 
form (11). In the case of an adverse event following BCG com-
plication, contacts were referred to the state tuberculosis medical 
officers for treatment. Ulcers were considered abnormal if they 
were larger than 10 mm diameter in size, or if they presented in 
combination with fever and malaise. Contacts were also checked 
for the presence of lymphadenopathy, abnormal scarring and 
keloids and if the course of the complication was different than 
normal. To document the size of the ulcers, pictures were taken of 
each BCG complication case and stored in a database.
Samples for immunological analysis
Blood was drawn from 15 contacts who developed an adverse 
event after receiving BCG vaccination. Two contacts were 
excluded from the analysis, because they later developed leprosy. 
Cytokine levels in WBA of 13 contacts with adverse events were 
analyzed and compared with those in contacts without (a scar 
or ulcer of <10  mm). WBA were performed for both groups 
and anti-phenolic glycolipid-I (PGL-I) serology cytokines and 
chemokines concentrations in supernatants were assessed.
2 www.ich.org (Accessed: March 19, 2018).
Whole Blood assays (WBa)
Venous blood was drawn from contacts at the time BCG compli-
cations occurred, which was on average 7.9 weeks after receiving 
BCG. As a control group, contacts without complications were 
tested. Controls were matched for age and gender as well as time 
point at which blood was drawn (on average 7.7 weeks; Table 2). 
Heparinized blood (4  mL) was directly added to microtubes 
pre-coated with M. leprae whole cell sonicate (WCS), M. leprae-
unique recombinant proteins ML2478 and ML0840 (designated 
Mlep) (22), or without antigen stimulus (designated NIL) 
(11, 23). After 24-h incubation at 37°C materials were frozen at 
−20°C, shipped on dry ice to the LUMC, and stored at −80°C 
until analysis.
Cytokine-Chemokine analysis
sCD40L, EGF, G-CSF, GM-CSF, GRO, IFN-α2, IFN-γ, IL-1α, 
IL-1β, IL-1ra, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12(p40), IL-12(p70), 
IL-17A, IP-10, MCP-1, MCP-3, MDC (CCL22), MIP-1α, MIP-1β, 
PDGF-AB/BB, PDGF-AA, RANTES, TGF-α, TNF-α, TNF-β, 
VEGF, and Eotaxin (CCL11) in WBA supernatants were measured 
with the Milliplex magnetic bead kit (Merck, USA) on 96 well 
multiscreen filter plates (Millipore, USA) using the Bio-Plex-100-
suspension-array-system (BioRad, Veenendaal) and analyzed 
using the Bio-Plex Manager software 6.1 (Bio-Rad Laboratories, 
Veenendaal, The Netherlands) (22). After pre-wetting the filter 
with assay solution, supernatant samples (25 µL) were added to 
the plates, together with 25-µL assay buffer and 25-µL beads, and 
the plates were incubated overnight at 4°C. After two washing 
steps with 200-µL wash buffer using a vacuum pump (Millipore, 
USA), 25-µL detection Ab mixture was added per well, and plates 
were incubated at room temperature in the dark for 1 h on a plate 
shaker at 300  rpm. Streptavidin-PE solution (25 µL per well) 
was added and incubated for 30 min at room temperature in the 
dark. After two washes, 150-µL Sheath Fluid was added to each 
well, and the plates were placed in the Bio-Plex System. From 
each well, a minimum of 50 analyte-specific beads were analyzed 
for fluorescence. A curve fit was applied to each standard curve 
according to the manufacturer’s manual. Sample concentrations 
were interpolated from these standard curves. Analyte concen-
trations outside the upper or lower limits of quantification were 
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assigned the values of the limits of quantification of the cytokine 
or chemokine.
PGl-i and M. leprae WCS
Synthesized disaccharide epitope [3,6-di-O-methyl-β-D-
glucopyranosyl(1→4)2,3-di-O-methylrhamnopyranoside], 
similar to M. leprae-specific PGL-I glycolipid, coupled to human 
serum albumin (synthetic PGL-I; designated ND–O–HSA) 
and M. leprae WCS, generated with support from the NIH/
NIAID Leprosy Contract N01-AI-25469, were obtained through 
the Biodefense and Emerging Infections Research Resources 
Repository3 (24).
PGl-i EliSa
IgM and IgG antibodies against synthetic PGL-I were detected 
as previously described adapted for the use of specific IgM 
and IgG antibody detection (22, 25). A synthetic analog of the 
M. leprae-specific PGL-I (ND–O–HSA) was coated onto high-
affinity polysorp Immulon 4HBX 96-well Nunc ELISA plates 
(Thermo Scientific, Rochester, NY, USA) using 200  ng/well in 
50-µL 0.1-M sodium carbonate/bicarbonate pH 9.6 (i.e., coating 
buffer) at 4°C overnight. Unbound Ag was removed by washing 
with PBS containing 0.05% Tween 20 (washing buffer) six times 
and wells were blocked with PBS containing 1% BSA (Roche 
Diagnostics, Germany) and 0.05% Tween 80 for 1  h at room 
temperature. 50 µL of 1:400 diluted serum/plasma (PBS/0.01% 
BSA as dilution buffer) was added to the wells and incubated for 
2 h at room temperature. After incubation, wells were washed six 
times with washing buffer, followed by the addition of 50 µL of 
1:8,000 antihuman IgM-HRP (Sigma A6907) or 1:4,000 antihu-
man IgG-HRP (DAKO P0214) and incubated for 2  h at room 
temperature. Following washing, the wells with the wash buffer, 
50 µL 3.3′,5.5′-tetramethylbenzidine (TMB) was added and the 
color reaction was stopped using H2SO4 after 10–15 min. The 
absorbance was determined at wavelength of 450 nm. Samples 
with an optical density (OD450), after correction for background, 
>0.20 were considered positive. The cutoff for positivity was 
determined by a threefold multiplication of the average value for 
non-endemic control individuals.
Statistical analysis
Statistical analysis was performed using GraphPad Prism version 
7 (GraphPad Software, San Diego, CA, USA),4 SPSS Statistics 24,5 
and R Version 3.3.0 (R, Vienna, Austria).6 A chi-square test was 
performed for contacts who developed BCG complications to 
identify potential differences compared with the control contacts’ 
characteristics (Table 1). A significance level of p ≤ 0.05 was used.
For identification of an immune biomarker signature associ-
ated with skin complications after BCG vaccination, a global 
test was used (26), which provided hierarchical clustering of the 
cytokines/chemokines based on absolute correlation difference 
3 http://www.beiresources.org/TBVTRMResearchMaterials/tabid/1431/Default.
aspx (Accessed: March 19, 2018).
4 http://www.graphpad.com (Accessed: March 19, 2018).
5 http://www.spss.com.hk (Accessed: March 19, 2018).
6 http://www.R-project.org (Accessed: March 19, 2018).
and average linkage. Moreover, the Mann–Whitney U test was 
performed to identify differences in group mean levels of host 
markers. The statistical significance level used was p  ≤  0.05. 
For significantly different markers in both the global test and 
Mann–Whitney U test, the diagnostic potential was assessed 
by receiver operating characteristic curve (ROC) analysis to 
determine the area under the curve (AUC). The cutoff values for 
optimal sensitivity and specificity were determined by calculating 
the Youden’s Index (27). To construct a biomarker profile, a linear 
discriminant analysis (LDA) was performed in SPSS. Analytes 
were ranked based on the pooled within-group correlations 
between discriminating variables and standardized canonical 
discriminant functions. The six most contributing analytes to 
the discriminant function were selected to construct a biomarker 
profile. The profile was constructed stepwise, determining the 
optimal sensitivity and specificity for each step. The optimal 
cutoff was determined per analyte after which each individual 
was designated positive or negative for all analytes separately.
rESUlTS
Occurrence of adverse Events after BCG 
Vaccination
Out of the 14,828 contacts who received BCG vaccination within 
the trial, 50 (0.34%) presented with vaccination-related adverse 
events (Table  1). The most common adverse events were skin 
ulcers (Table S1 in Supplementary Material; Figure 1A). A total 
of 40 contacts (80%) developed large skin ulcers varying between 
10 and 35 mm; four of these also had axillary lymphadenopathy 
and one had enlarged lymph nodes. One ulcer was 8 mm, but 
was included as adverse event because the contact also reported 
malaise and mild fever. Keloids (Figure  1B) were present in 
eight contacts, of whom three were small (<1  cm) and three 
were >1 cm. One contact developed a persistent keloid, which 
was first signaled 1 year after receiving BCG vaccination. When 
excluding the contact with persistent keloid, the average time 
between BCG vaccination and initiation of complication in the 
50 contacts was 5.5 weeks.
Variations in BCG-Vaccination-related 
adverse Events
In four contacts, adverse events manifested differently: one woman 
developed an abscess, which was incised and drained at home 
3 months after vaccination, then developed intermittent fever and 
was treated unsuccessfully with various antibiotics of unknown 
kind provided by different doctors. After 1 year, the contact was 
admitted for investigation, because of an erythematous nodule 
(2  cm ×  2  cm) surrounded by scarring. She was re-incised by 
a plastic surgeon upon suspicion of a deep-seated abscess. The 
histological report of the biopsy showed a keloid scar (Figure 1B).
A second contact had a persistent pustule of 5 mm 5 months 
after receiving BCG, felt weak, and had coughed for the past 2 
months. She only had a 2-day history of fever and was tested 
sputum-negative for acid-fast bacilli (AFB). The pustule was 
not opened, but kept clean and dry and healed after a course of 
flucloxacillin.
FiGUrE 1 | Representative examples of skin complications after BCG vaccination. (a) Three contacts with big ulcers (>10 mm). (B) A contact with keloid (picture 
taken before operation). (C) A contact with an ulcer and lymphadenitis who developed leprosy at follow-up.
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A third contact had developed a large scar (12 mm × 10 mm) 
and many small ulcers on both arms and legs after receiving BCG. 
She received unknown medication from an outside doctor and 
the lesions healed.
Finally, the fourth contact presented with an ulcer at the BCG 
injection site of 10 mm × 15 mm and mild left axillary lymphad-
enopathy. Already before BCG vaccination, the contact had a 
history of occasional fever and pain palpable on the ribs, which 
was treated with pain killers. He had no known contact to TB 
patients, and was sputum- and X-ray negative for TB.
In addition to adverse events, two contacts also developed 
leprosy following BCG vaccination (Figure  1C). One had a 
small keloid, and the other had an ulcer of 15 mm × 20 mm with 
lymphadenitis (Figure 1B).
The average age at the time of the adverse event was 30 years, 
with a range of 6 to 80 years. Similar numbers of males and females 
were identified with adverse events (Table  1). More than half 
(60%) received a revaccination, based on the presence of a BCG 
scar. A higher number of children aged between 5 and 16 years 
old (as aged under 5s were excluded) developed BCG adverse 
events compared with adults (0.43% versus 0.29%); however, 
this number was not statistically significant (p = 0.16; Table 1). 
A slightly higher but statistically not significant number of con-
tacts who received BCG for the second time developed adverse 
events compared with those who lacked a BCG scar (0.35% versus 
0.32%; p = 0.68). Despite that an almost double amount of contacts 
developed adverse events when the index patient had multibacil-
lary (MB) leprosy, compared with paucibacillary (PB) leprosy, this 
increase was not statistically significant either (p = 0.08).
Among the 13 contacts with an adverse event after BCG from 
whom blood was analyzed, nine had large ulcers >10 mm, one 
patient had an ulcer of 8 mm, but with general malaise, one had a 
keloid, one had a big scar, and one had an enlarged lymph node.
anti-PGl-i igM levels
To estimate whether the extent of seropositivity in contacts of lep-
rosy patients could already indicate whether complications could 
occur after BCG vaccination, the levels of anti-M. leprae PGL-I 
IgM antibodies, as estimated by the optical density at 450  nm 
(OD450), were measured in sera of 26 individuals: 13 with and 13 
without BCG complications (Figure 2). Three contacts from both 
groups were seropositive for IgM against PGL-I (OD450 > 0.2), but 
no significant differences were observed between both groups.
immune Profiles Coinciding With adverse 
Events after BCG Vaccination
To assess what type of immune profile (i.e., combinations of 
cytokines in M. leprae-stimulated WBA) is associated with 
FiGUrE 2 | Mycobacterium leprae phenolic glycolipid-I (PGL-I)-specific 
antibodies in contacts of leprosy patients with or without BCG-induced skin 
complications. IgG and IgM antibodies directed against synthetic PGL-I 
(ND–O–HSA) were determined by ELISA. Samples with OD450 (corrected for 
background OD) >0.2 were considered seropositive. No statistically different 
levels of IgG and IgM antibodies were observed between the contacts with 
(+ ; gray dots) or without (−; black squares) complications.
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was optimal, as addition of a sixth marker slightly decreased the 
AUC from 0.96 to 0.93 (Table 3).
DiSCUSSiOn
Within a cluster randomized controlled BCG vaccination trial 
in contacts of leprosy patients in Bangladesh, adverse events 
were observed in 0.34% of the recipients. These complications 
consisted primarily (80%) of skin ulcerations and were associated 
with increased Th1 immunity, inflammation and reduced T-cell 
regulation in WBA.
Although serious adverse events after BCG vaccination are 
rare, as many as 95% of BCG recipients have an uncomplicated, 
local reaction at the site of inoculation, characterized by the 
appearance of a pustule in combination with pain, swelling, and 
erythema within 2 to 3 weeks after vaccination. In approximately 
70% of the cases, ulceration with drainage occurs at the vaccine 
site after about 6 weeks, resulting in a lesion of about 5 mm in 
diameter. Lesions usually heal within 3 months with permanent 
residual scarring at the vaccination site. Rare local abscesses and 
ulcers usually occur between 1 and 5 months post-vaccination, 
but adverse events have also been reported after longer periods 
of time (28). Lymphadenopathy occurs in the drainage area of the 
vaccinated site, so is most common in the axilla and sometimes in 
the cervical lymph nodes (28). Even more uncommon are serious 
adverse events such as osteitis, osteomyelitis and disseminated 
infection (19). Disseminated disease following BCG vaccination 
occurs usually with immunosuppression, such as HIV-infection 
(16) or genetic immune deficiency (29), which develops in less 
than one in a million (20).
The incidence of adverse events of 0.34% in this study is 
comparable with the 0.02 to 5% described in previous studies 
(13–15, 18, 28). A trial evaluating the incidence of adverse events 
to primary and booster BCG vaccination in schoolchildren in 
Salvador, Bahia (Brazil) (14) observed a rate of 0.35 per 1,000 
vaccinations, without lethal cases or disseminated infections. 
Although not statistically significant, adverse events after booster 
vaccinations were approximately twice the rate compared with 
primary vaccination with BCG. The median time to onset of 
complications was 26  days, 12  days shorter than observed in 
Bangladesh. Similarly, 0.38 out of 1,000 vaccinated individuals 
developed complications in a study in the Brazilian Amazon (15). 
In contrast, the risk in the group receiving a revaccination was 
only >1.05 in the group receiving a first dose, similar to what 
we found in our Bangladesh study (0.35 versus 0.32%; p = 0.68).
The presence of a BCG scar is considered a highly sensitive 
indicator of the vaccination status as 92% of individuals aged 
1–4 months at vaccination, develops a visible scar at 7–12 months 
of age, which declines to 84% at 4 years (12). When BCG is 
given to an infant before they are 1 month old, 90% has a scar at 
7–12 months of age and 76% has a scar at 4 years. In this study, we 
used the absence of a BCG scar to designate the lack of previous 
(childhood) vaccination. However, since 16–24% of BCG vac-
cinated individuals do not develop a scar, it could be that a larger 
number of individuals actually received a BCG booster in the 
MALTALEP trial than is estimated solely based on the presence 
of a scar.
BCG-related complications, a global test (26) was performed on 
all 32 cytokines stratified by stimulus used in the WBA (Figure 3). 
This analysis showed that three analytes were significantly differ-
ent between the two contact groups: decreased levels of sCD40LNIL 
(soluble cluster of differentiation ligand 40, without stimula-
tion) and GROWCS (growth-regulated oncogene, in response to 
M. leprae WCS) were significantly associated with occurrence of 
BCG complications (p = 0.03 and 0.013, respectively; Figures 3 
and 4). In contrast, increased levels of IFN-γ in response to 
M. leprae-specific proteins (IFN-γMlep; p = 0.012) were observed 
in individuals developing BCG complications (Figures 3 and 4). 
Individually these three markers enable a good distinction 
between contacts with BCG-related complications and those 
without, showing an AUC of 0.75 for sCD40L and 0.78 for both 
GROWCS and IFN-γMlep (Figure 3). Using a LDA three additional 
markers CCL4NIL, IL-6Mlep, and GCSFNIL that were decreased in 
individuals with adverse events, were identified, that improved 
the signature for adverse events. Next, the six analytes were ranked 
based on their contribution to the discriminant function and 
sequentially added to the biomarker profile (Table 3) and scored 
for each individual as positive or negative based on the optimal 
cutoff. This showed that optimal sensitivity (100%) was observed 
for the combination of sCD40LNIL, IFN-γMlep, and GROWCS show-
ing 76% specificity and an AUC of 0.94 (p < 0.0001). On the other 
hand, optimal specificity (100%) was achieved by a five marker 
profile (sCD40LNIL, IFN-γMlep, GROWCS, CCL4NIL, and IL-6 Mlep), 
with a sensitivity of 84% and an AUC of 0.96. The cutoff of >3.5 
indicates that none of the contacts without complications scores 
positive for more than 4 out of 5 markers, thereby showing addi-
tion of markers improves the specificity. The five marker profile 
FiGUrE 3 | Cytokine concentrations in 24-h whole-blood assays (WBA) with or without stimulation with Mycobacterium leprae (M. leprae) unique proteins (Mlep) or 
M. leprae whole cell sonicate (WCS) in contacts with and without BCG complications (left panels). The global test (26) indicated that sCD40Lmed, GROwcs, and 
IFN-γMlep were significantly different between BCG-vaccinated contacts of leprosy patients with BCG-related complications and those without. This was confirmed by 
a Mann–Whitney U test. *p < 0.05–0.01. Receiver operating characteristic curves (ROCs) were computed and the area under the curve (AUC) is indicated for each 
analyte (right panels). The limits of detections for sCD40Lmed were 1.5–10,000, for GROwcs were 12.5–9,600. and IFN-γMlep were 2–10,000.
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The development of leprosy after BCG vaccination can be 
considered an ultimate adverse event. In a previous study (30), 
we observed an unexpectedly high proportion of new leprosy 
patients (mainly PB and leprosy type-1 reactions) among appar-
ently healthy HCs of leprosy patients within the first 3 months 
after BCG vaccination (0.4% of vaccinated contacts). Of these, 
43% had a BCG scar before vaccination in the trial. However, it 
remains unclear whether BCG vaccination merely catalyzes the 
formation of clinical symptoms in individuals who are bound to 
develop leprosy, or whether patients would not have developed 
the disease without this vaccination.
Several recent studies show that BCG alters the innate 
immune system by trained immunity (5–7). The protective effect 
against TB induced by neonatal BCG vaccination coincides with 
FiGUrE 4 | Results of whole-blood assays (WBAs) in contacts with and without BCG complications in (a) medium (designated NIL). (B) Mycobacterium leprae 
whole cell sonicate (designated WCS). (C) ML2478/ML0840 recombinant proteins (designated Mlep) (C).
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protection against heterologous pathogens. This effect is charac-
terized by decreased anti-inflammatory cytokine responses, but 
increased IL-6 in unstimulated samples (8). In another study, a 
BCG vaccination-induced increase in IL-6, EGF, and PDGF-AB/
BB and decrease in IP-10, IL-2, IL-13, IL-17, GM-CSF, and GRO 
was observed in response to various non-specific innate immunity 
TaBlE 3 | Ability of analytes to distinguish contacts with adverse events in whole blood assays.
Single markers Signature
Step analyte Correlation Stimulus p-value aUC Sens. Spec. Cutoff
1 sCD40L 0.086 NIL 0.0262 0.75 85% 54%  <289
2 IFN-γ 0.076 Mlep 0.0124 0.83 62% 92%  >1.5
3 GRO 0.070 WCS 0.0126 0.94 100% 76%  >1.5
4 CCL4 0.066 NIL 0.1254 0.94 92% 85%  >2.5
5 IL-6 −0.055 Mlep 0.2234 0.96 84% 100%  >3.5
6 GCSF 0.043 NIL 0.2428 0.93 85% 92%  >3.5
Step-by-step addition of analytes ranked by absolute size of correlation within discriminant function. For each step, the analyte that was added to the signature specific for 
occurrence of BCG vaccination-related adverse events, the absolute size of correlation generated from the linear discriminant analysis, the stimulus, p-value (Mann–Whitney U test), 
area under the curve (AUC), and the sensitivity (sens.) and specificity (spec.) based on the optimal cutoff are shown. The following three different stimuli used were: M. leprae whole 
cell sonicate (WCS), ML2478/ML0840 recombinant proteins (Mlep), or without antigen stimulus (NIL).
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stimuli (PAM3Cys, C. albicans, and S. aureus). Along with this 
cytokine biomarker signature, increased CD69 expression on 
NK cells was observed as well (Dockrell, 2017 #483).
T-helper 1 (Th1) host-cellular immunity is generally con-
sidered to be key in controlling mycobacterial infections (31). 
However, clinical presentation of tuberculoid leprosy as well as 
type-1 (reversal) reactions also coincides with strong M. leprae-
specific Th1 immunity and high levels of pro-inflammatory 
cytokines (32).
Despite the apparent homology between the mycobacteria, 
BCG but not M. leprae can stimulate monocytes to initiate a 
protective type-1 cascade (33). Moreover, in  vitro exposure 
of monocytes from healthy donors to M. leprae (or M. leprae 
PGL-I) reduced levels of Th1-type cytokines and expression 
of macrophage type-1 (Mϕ1) cell surface markers (33). In 
contrast, ex vivo stimulation of peripheral blood mononuclear 
cells (PBMCs) with BCG or purified protein derivative of 
tuberculin (PPD) from 10-week-old infants in South Africa, 
who had received neonatal BCG vaccination, showed upregula-
tion of mϕ1-associated genes whereas mϕ2 associated genes 
were down-regulated (34), indicating BCG-induced protective 
immunity. Also, in response to M. leprae, monocytes from 
these infants released higher levels of inflammatory cytokines 
TNF-α and IL-1β compared with monocytes from unvaccinated 
infants (33). Similarly, cytokine profiles of infants from the 
United Kingdom receiving BCG vaccination (35) showed that a 
higher number of IFN-γ+ TNF-α+ IL-2+ multifunctional CD4+ 
T cells were associated with growth inhibition of mycobacteria. 
Although T-cell activation (HLA-DR+CD4+ T cells) was a risk 
factor for TB disease, increased numbers of BCG-specific T cells 
secreting IFN-γ were detected in BCG vaccinated infants with-
out TB (36). These studies indicate that pro-inflammatory Th1 
immunity, although not the only factor, is associated with BCG-
induced protection against tuberculosis. Similarly, the Mitsuda 
reaction measures whether an adequate immune response 
to an intradermal injection of the heat-killed leprosy bacilli 
(lepromin) is initiated, as it has a good prognostic value for 
susceptibility (when negative) or resistance (when positive) to 
the lepromatous form of leprosy (37). In line with that it was also 
observed that individuals that showed large local reactogenicity 
after intradermal BCG administration or lepromin injection are 
reported to have less risk for leprosy onset (38).
In a BCG vaccination study in 12 tuberculin skin test (TST) 
and Quantiferon negative, BCG- naïve adults in The Netherlands, 
local skin reactions varied strongly between individuals (17). 
It was observed that BCG vaccination induced significant Th1-type 
immunity (CD4+ IFN-γ+, IL-2+ TNF-α+ and CD8+ IFN-γ+ T cells) 
in those that presented with high local inflammation responses, 
with a peak 8-week post-vaccination. Of note is that BCG vaccina-
tion significantly increased regulatory CD8+ T cells such as CD25+ 
Foxp3+ CD39+ CD8+ T cells as well as CD25+ Foxp3+ CD39+ LAG-
3+ CCL4+ CD8+ T cells in low inflammation responders.
Similarly, individuals who developed (skin) complications in 
Bangladesh also produced higher levels of IFN-γ in response to 
M. leprae antigens around 8 weeks (average 7.9) post-vaccination, 
although at least 8 out of 13 contacts with BCG complications 
were not BCG-naïve and the a  priori chance of exposure to 
mycobacteria was considerably larger. In contrast to the Dutch 
cohort, CRP levels were high in both groups and did not differ 
significantly (Figure S2 in Supplementary Material).
Of note in the current study are the lower levels of sCD40LNIL 
and GROWCS that were significantly associated with BCG com-
plications, concomitantly with elevated IFN-γ levels in response 
to M. leprae unique proteins (IFN-γMlep). GRO (CXCL1) is 
expressed by macrophages, neutrophils and epithelial cells and 
has neutrophil chemoattractant activity. Although the role of 
GRO in leprosy pathology has not been investigated, increase in 
GRO levels can reduce severity of multiple sclerosis (39). This 
neuroprotective role for CXCL1 could well be consistent with the 
onset of complications upon its reduction after M. leprae WCS 
stimulation as observed in our study. Moreover, in UK-born, 
BCG-vaccinated infants the levels of GRO in response to non-
specific innate immunity stimuli were suppressed as well, in line 
with our finding in Bangladesh (5).
Recently, it was shown that higher levels of sCD40L present in 
serum of patients with Behçet’s disease caused a strong stimulus 
on the production of reactive oxygen species (40). Thus, the 
reduction in sCD40L observed in contacts with complications 
could indicate a weaker ability to combat BCG bacilli locally 
leading to tissue destruction at the vaccination site.
Besides induction of activated T cells, BCG vaccination can also 
induce regulatory T cells (Tregs), in particular CD8+ T cells which 
dampen the inflammatory response to mycobacteria (41, 42) 
and lead to inadequate killing of mycobacteria (43). Likewise, 
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Tregs have been isolated from lepromatous leprosy patients, who 
in contrast to tuberculoid patients display reduced Th1 immunity 
and capacity to kill M. leprae bacteria (44). The breakdown of 
T-cell regulation, in favor of inflammation, underlies the etiology 
of tissue damage in tuberculoid leprosy and leprosy reactions (45).
Regulatory T cells can suppress Th1 cells through the secretion 
of CC chemokine ligand 4 (CCL4) (42). In this study, a reduc-
tion in CCL4 (although not significant) could indicate decreased 
T-cell regulation in individuals with complications, causing a 
shift in the equilibrium toward excessive Th1-type immunity 
with corresponding inflammation at the BCG vaccination site. 
However, further research will be required to identify in detail 
the cellular subtypes involved. Furthermore, the leprosy contacts 
with high inflammatory responses after BCG vaccination could 
therefore also be more likely to develop tuberculoid leprosy. 
In line with this hypothesis are the two cases out of the 50 contacts 
in this study with BCG complications, who developed border line 
tuberculoid leprosy (BT).
COnClUSiOn
The rate of documented adverse events after BCG vaccination in 
the studied Bangladesh cohort of leprosy patients’ contacts was 
low (0.34%), and comparable to studies in other countries.
Contacts with BCG complications showed increased M. leprae- 
specific Th1-type immunity but a tendency of reduced T-cell 
regulation in WBA with corresponding inflammation at the 
BCG vaccination site indicating improved protection against 
M. leprae. In addition, these individuals may also be at a higher 
risk of developing tuberculoid leprosy after M. leprae infection.
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